CellaVision AB hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü yıllık ödenmektedir ve son temettü hariç tarihi May 7, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$2.25
May 7, 2025
Ödeme Sıklığı
Ödeme Oranı
Yıllık
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
May 7, 2025
$2.50
May 8, 2025
May 13, 2025
May 6, 2024
$2.25
May 7, 2024
May 13, 2024
May 8, 2023
$2.25
May 9, 2023
May 12, 2023
May 12, 2022
$2.00
May 13, 2022
May 18, 2022
Apr 30, 2021
$0.75
May 3, 2021
May 6, 2021
May 9, 2019
$1.50
May 10, 2019
May 15, 2019
Dividend Grafikleri
CVLLY Kâr Payları
CVLLY Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
CellaVision AB'in şu anki temettü ödemesi ve yıllık temettüsü nedir?
CellaVision AB'in temettü ödeme oranı nedir?
CVLLY'ün temettü dağıtım tarihi nedir?
CellaVision AB ne sıklıkla temettü öder?
Önemli İstatistikler
Önceki Kapanış
--
Açılış fiyatı
--
Günün Aralığı
-
52 haftalık aralık
-
İşlem hacmi
--
Ort.Hacim
--
EPS (TTM)
--
Dividend yield
--
Piyasa Değeri
--
CVLLY nedir?
CellaVision AB engages in the provision of digital microscopy solutions for hematology laboratories. The company is headquartered in Lund, Skane and currently employs 230 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.